Professionals

Publicaties

Over de afgelopen jaren hebben wij bijdragen geleverd aan diverse nationale en internationale publicaties betreffende ons onderzoeksveld.

Selectie van recente publicaties

2024

Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands. Pennings, E. R. A., Durmaz, M. J., Visser, O., Posthuma, E. F. M., Issa, D. E., Chamuleau, M. E. D., Lugtenburg, P. J., Kersten, M. J. & Dinmohamed, A. G., 1 Dec 2024, In: Blood Cancer Journal. 14, 1, 3. .

 

Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia. Chen, Z., Cretenet, G., Carnazzo, V., Simon-Molas, H., Kater, A. P., Windt, G. J. W. V. D. & Eldering, E., 1 Jan 2024, In: Haematologica. 109, 1, p. 151-162 12 p. .

2023

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients. de Jonge, A. V., van Werkhoven, E., Dinmohamed, A. G., Nijland, M., Zwinderman, A. H., Bossuyt, P. M., Veldhuis, M. S., Rutten, E. G. G. M., Mous, R., Vermaat, J. S. P., Sandberg, Y., de Jongh, E., Bilgin, Y. M., Boersma, R., Koene, H., Kersten, M. J., de Jong, D. & Chamuleau, M. E. D., 1 Dec 2023, In: Blood Cancer Journal. 13, 1, 85. .

 

CAR Traffic jam: who can use the fast lane? . Kuipers, M. T. & Kersten, M. J., 12 Oct 2023, In: Blood. 142, 15, p. 1257-1258 2 p. .

 

Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors. Martens, A. W. J., Kavazovi?, I., Krapi?, M., Pack, S. M., Arens, R., Jongejan, A., Moerland, P. D., Eldering, E., van der Windt, G. J. W., Wensveen, F. M., Peters, F. S. & Kater, A. P., Mar 2023, In: Leukemia. 37, 3, p. 606-616 11 p. .

 

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019. van der Straten, L., Levin, M-D., Dinnessen, M. A. W., Visser, O., Posthuma, E. F. M., Doorduijn, J. K., Langerak, A. W., Kater, A. P. & Dinmohamed, A. G., Dec 2023, In: Blood Cancer Journal. 13, 1, p. 15 1 p., 15. .

 

Inhibiting BTK in Chronic Lymphocytic Leukemia. Kater, A. P. & Eichhorst, B., 6 Jul 2023, In: The New England journal of medicine. 389, 1, p. 83-86 4 p. .

 

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia. Montironi, C., Jacobs, C. F., Cretenet, G., Peters, F. S., Schomakers, B. V., van Weeghel, M., Kater, A. P., Simon-Molas, H. & Eldering, E., 2023, In: Blood advances. 7, 21, p. 6540-6552 13 p. .

 

Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia. Haggenburg, S., Garcia Garrido, H. M., Kant, I. M. J., van der Straaten, H. M., de Boer, F., Kersting, S., Issa, D., te Raa, D., Visser, H. P. J., Kater, A. P., Goorhuis, A. & de Heer, K., 1 Jul 2023, In: Vaccines. 11, 7, 1201. .

 

JAK–STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL. Haselager, M. V., Thijssen, R., Bax, D., Both, D., de Boer, F., Mackay, S., Dubois, J., Mellink, C., Kater, A. P. & Eldering, E., Jun 2023, In: Molecular Oncology. 17, 6, p. 1112-1128 17 p. .

 

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival. Haselager, M. V., van Driel, B. F., Perelaer, E., de Rooij, D., Lashgari, D., Loos, R., Kater, A. P., Moerland, P. D. & Eldering, E., 23 Sept 2023, In: HemaSphere. 7, 9, p. E938.

 

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation. Kielbassa, K., Haselager, M. V., Bax, D. J. C., van Driel, B. F., Dubois, J., Levin, M-D., Kersting, S., Svanberg, R., Niemann, C. U., Kater, A. P. & Eldering, E., Jun 2023, In: Leukemia. 37, 6, p. 1268-1276 9 p. .

 

AKT supports the metabolic fitness of multiple myeloma cells by restricting FOXO activity. Bloedjes, T. A., de Wilde, G., Khan, G. H., Ashby, T. C., Shaughnessy, J. D., Zhan, F., Houtkooper, R. H., Bende, R. J., van Noesel, C. J. M., Spaargaren, M. & Guikema, J. E. J., 9 May 2023, In: Blood advances. 7, 9, p. 1697-1712 16 p.

 

ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non-myeloablative conditioning. Aydin, M., de Leeuw, D. C., Rutten, C. E., Visser, O. J., Tang, MW., van Roessel, C., Janssen, J. J. W., Biemond, B. J., van de Loosdrecht, A. A., Hazenberg, M. D., Meijer, E. & Nur, E., Nov 2023, In: British journal of haematology. 203, 3, p. 439-445 7 p.

 

Gut microbiome in allogeneic HCT survivors: The insults are gone but the damage lingers. van Lier, Y. & Hazenberg, M. D., May 2023, In: British journal of haematology. 201, 4, p. 602-604 3 p.

 

Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease van Lier, Y. F., Vos, J., Blom, B. & Hazenberg, M. D., 2023, In: Gut Microbes. 15, 1, 2178805.

 

What's brewing for MALT1 in lymphoma? . Spaargaren, M., 7 Dec 2023, In: Blood. 142, 23, p. 1939-1941 3 p.

 

Cellular therapy in lymphoma. Sureda, A., Lugtenburg, P. J., Kersten, M. J., Subklewe, M., Spanjaart, A., Shah, N. N., Kerbauy, L. N., Roddie, C., Pennings, E. R. A., Mahuad, C., Poon, M., Hendricks, C. L., Kamdar, M. & Jacobson, C., 2023, (E-pub ahead of print) In: Hematological oncology.

 

Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2 the International Agency for Research on Cancer/World Health Organization, Sept 2023, In: Leukemia. 37, 9, p. 1944-1951 8 p. .

 

Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities. Spanjaart, A. M., Pennings, E. R. A., Kos, M., Mutsaers, P. G. N. J., Lugtenburg, P. J., van Meerten, T., van Doesum, J. A., Minnema, M. C., Jak, M., van Dorp, S., Vermaat, J. S. P., van der Poel, M. W. M., van Oijen, M. G. H., Kuipers, M. T., Nijhof, I. S. & Kersten, M. J., 1 Mar 2023, In: JCO oncology practice. 19, 3, p. E407-E416.

 

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia. Dogliotti, I., Jiménez, C., Varettoni, M., Talaulikar, D., Bagratuni, T., Ferrante, M., Pérez, J., Drandi, D., Puig, N., Gilestro, M., García-Álvarez, M., Owen, R., Jurczak, W., Tedeschi, A., Leblond, V., Kastritis, E., Kersten, M. J., D’Sa, S., Kaš─Źák, M., Willenbacher, W., & 10 others, Feb 2023, In: Leukemia. 37, 2, p. 388-395 8 p. .

 

Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment. Stevens, W. B. C., Los-de Vries, G. T., Langois-Jacques, C., Clear, A. J., Stathi, P., Sander, B., Rosenwald, A., Calaminici, M., Hoster, E., Hiddemann, W., Gaulard, P., Salles, G., Klapper, W., Xerri, L., Burton, C., Tooze, R. M., Smith, A. G., Buske, C., Scott, D. W., Natkunam, Y., & 11 others, 5 Apr 2023, In: HemaSphere. 7, 4, p. E863.

 

Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy. de Boer, J. W., Pennings, E. R. A., Kleinjan, A., van Doesum, J. A., Spanjaart, A. M., Mutsaers, P. G. N. J., Jak, M., van der Poel, M. W. M., Kuipers, M. T., Adam, J. A., Diepstra, A., Koens, L., van Dorp, S., Vermaat, J. S. P., Niezink, A. G. H., Kersten, M. J. & van Meerten, T., 2023, In: Blood advances. 7, 21, p. 6710-6716 7 p. .

 

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation. Thus, Y. J., de Rooij, M. F. M., Swier, N., Beijersbergen, R. L., Guikema, J. E. J., Kersten, M-J., Eldering, E., Pals, S. T., Kater, A. P. & Spaargaren, M., 1 Mar 2023, In: Haematologica. 108, 3, p. 797-810 14 p. .

 

MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas. Minderman, M., Lantermans, H. C., Grüneberg, L. J., Cillessen, S. A. G. M., Bende, R. J., van Noesel, C. J. M., Kersten, M. J., Pals, S. T. & Spaargaren, M., Dec 2023, In: Blood Cancer Journal. 13, 1, p. 37 37. .

 

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: A population-based study. Geerdes, E. E., Durmaz, M. J., Lugtenburg, P. J., Chamuleau, M. E. D., Visser, O., Issa, D. E., Brouwer, R. E., Posthuma, E. F. M., Zijlstra, J. M., Kersten, M. J. & Dinmohamed, A. G., 12 Sept 2023, In: Blood. 7, 17, p. 4869-4873 5 p. .

 

Patient preferences regarding treatment options for Waldenström's macroglobulinemia: A discrete choice experiment. Amaador, K., Nieuwkerk, P. T., Minnema, M. C., Kersten, M. J. & Vos, J. M. I., Feb 2023, In: Cancer Medicine. 12, 3, p. 3376-3386 11 p. .

 

Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma. Kersten, M. J., Qiao, Y., Shah, R., Solem, C., Snider, J. T., To, C., Cheng, P., Spooner, C. & Perales, M-A., May 2023, In: Transplantation and Cellular Therapy. 29, 5, p. 335.e1-335.e8.

 

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain. Minderman, M., Lantermans, H., van der Zwaan, C., Hoogendijk, A. J., van den Biggelaar, M., Kersten, M. J., Spaargaren, M. & Pals, S. T., 1 Dec 2023, In: Blood Cancer Journal. 13, 1, 125. .

 

Treatment of relapsed and refractory Waldenstrom Macroglobulinemia. Amaador, K., Kersten, M. J., Minnema, M. C. & Vos, J. M. I., 2023, In: Leukemia and Lymphoma. 64, 1, p. 30-41 12 p. .

 

2022

A BAFFling ménage à trois in mantle cell lymphoma. Eldering, E., 1 Dec 2022, In: Haematologica. 107, 12, p. 2774-2775 2 p.

 

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. de Rooij, M. F. M., Thus, Y. J., Swier, N., Beijersbergen, R. L., Pals, S. T. & Spaargaren, M., 1 Dec 2022, In: Nature communications. 13, 1, 2136.

 

Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Chen, Z., Simon-Molas, H., Cretenet, G., Valle-Argos, B., Smith, L. D., Forconi, F., Schomakers, B. V., van Weeghel, M., Bryant, D. J., van Bruggen, J. A. C., Peters, F. S., Rathmell, J. C., van der Windt, G. J. W., Kater, A. P., Packham, G. & Eldering, E., 11 Aug 2022, In: Blood. 140, 6, p. 630-643 14 p.

 

CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Munir, T., Moreno, C., Owen, C., Follows, G., Benjamini, O., Janssens, A., Levin, M-D., Osterborg, A., Robak, T., Simkovic, M., Stevens, D., Voloshin, S., Vorobyev, V., Yagci, M., Ysebaert, L., Qi, Q., Steele, A., Schuier, N., Baeten, K., Caces, D. B., Niemann, C., Kater, A.P., 1 Oct 2022, In: Clinical Lymphoma, Myeloma and Leukemia. 22, p. S264-S265

 

Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. Kersten, M. J., Amaador, K., Minnema, M. C., Vos, J. M. I., Nasserinejad, K., Kap, M., Kastritis, E., Gavriatopoulou, M., Kraan, W., Chamuleau, M. E. D., Deeren, D., Tick, L. W., Doorduijn, J. K., Offner, F., Böhmer, L. H., Liu, R. D., Pals, S. T. & Dimopoulos, M. A., 1 Jan 2022, In: Journal of clinical oncology. 40, 1, p. 40-51 12 p.

 

Do CARs finally hit the CLL road? Kater, A. P. & Melenhorst, J. J., 24 Mar 2022, In: Blood. 139, 12, p. 1775-1776 2 p.

 

Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline. Amaador, K., Kersten, M. J., Minnema, M. C. & Vos, J. M. I., Jul 2022, In: HemaSphere. 6, 7, p. e746

 

GATA2 haploinsufficient patients lack innate lymphoid cells that arise after hematopoietic cell transplantation. van Lier, Y. F., Krabbendam, L., Haverkate, N. J. E., Zeerleder, S. S., Rutten, C. E., Blom, B., Spits, H. & Hazenberg, M. D., 3 Oct 2022, In: Frontiers in immunology. 13, 1020590.

 

IgM monoclonal gammopathies of clinical significance: diagnosis and management. Khwaja, J., D’Sa, S., Minnema, M. C., Kersten, M. J., Wechalekar, A. & Vos, J. M. I., 1 Sep 2022, In: Haematologica. 107, 9, p. 2037-2050 14 p.

 

Increasing CART cell engine performance in CLL. Peters, F. S. & Kater, A. P., 27 Jan 2022, In: Blood. 139, 4, p. 473-474 2 p.

 

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation. Thus, Y. J., De Rooij, M. F. M., Swier, N., Beijersbergen, R. L., Guikema, J. E. J., Kersten, M-J., Eldering, E., Pals, S. T., Kater, A. P. & Spaargaren, M., 13 Oct 2022, (E-pub ahead of print) In: Haematologica.

 

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Kater, A. P., Levin, M-D., Dubois, J., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., van der Kevie-Kersemaekers, A-M. F., Dobber, J. A., Poulsen, C. B., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J., Brieghel, C., Mattsson, M., Bellido, M., Tran, H. T. T., & 2 others, 1 Jun 2022, In: The Lancet Oncology. 23, 6, p. 818-828 11 p.

 

Patient preferences regarding treatment options for Waldenström's macroglobulinemia: A discrete choice experiment. Amaador, K., Nieuwkerk, P. T., Minnema, M. C., Kersten, M. J. & Vos, J. M. I., 2022, (E-pub ahead of print) In: Cancer Medicine.

 

Presence of innate lymphoid cells in allogeneic hematopoietic grafts correlates with reduced graft-versus-host disease. Kroeze, A., van Hoeven, V., Verheij, M. W., Turksma, A. W., Weterings, N., van Gassen, S., Zeerleder, S. S., Blom, B., Voermans, C. & Hazenberg, M. D., 1 Mar 2022, In: Cytotherapy. 24, 3, p. 302-310 9 p.

 

Refractory Stage M Ganglioneuroblastoma with Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort. Tas, M. L., Molenaar, J. J., Peek, A. M. L., Lequin, M. H., Verdijk, R. M., de Krijger, R. R., Tytgat, G. A. M. & van Noesel, M. M., 1 Jan 2022, In: Journal of Pediatric Hematology/Oncology. 44, 1, p. E5-E13

 

Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. Amaador, K., Wieske, L., Koel-Simmelink, M. J. A., Kamp, A., Jongerius, I., de Heer, K., Teunissen, C. E., Minnema, M. C., Notermans, N. C., Eftimov, F., Kersten, M. J. & Vos, J. M. I., Jul 2022, In: Journal of neurology. 269, 7, p. 3700-3705 6 p.

 

SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma. Leeksma, A. C., Derks, I. A. M., Garrick, B., Jongejan, A., Colombo, M., Bloedjes, T., Trowe, T., Leisten, J. C., Howarth, M., Malek, M., Mortensen, D. S., Blease, K., Groza, M. C., Narla, R. K., Loos, R., Kersten, M-J., Moerland, P. D., Guikema, J. E. J., Kater, A. P., Eldering, E., & 1 others, 18 Nov 2022, (E-pub ahead of print) In: Molecular Oncology.

 

T-cell subset composition and functionality in patients with Waldenström’s macroglobulinemia. Amaador, K., Martens, A., de Boer, R., Rietveld, J., Heemskerk, M., Rutten, C. E., Eldering, E., Kersten, M-J., Kater, A. P., Vos, J. & Tonino, S., Jun 2022, In: Leukemia & lymphoma. 63, 6, p. 1469-1473 5 p.

 

The earliest events in BRAF-mutant colorectal cancer: exome sequencing of sessile serrated lesions with a tiny focus dysplasia or cancer reveals recurring mutations in two distinct progression pathways. Bleijenberg, A. G. C., IJspeert, J. E. G., Mulder, J. B. G., Drillenburg, P., Stel, H. V., Lodder, E. M., Carvalho, B., Jansen, J., Meijer, G., van Eeden, S., Dekker, E. & van Noesel, C. J. M., Jun 2022, In: Journal of pathology. 257, 2, p. 239-249 11 p.

 

The Therapeutic Potential of Targeting NIK in B Cell Malignancies. Haselager, M. V. & Eldering, E., 12 Jul 2022, In: Frontiers in immunology. 13, 930986.

 

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Thus, Y. J., Eldering, E., Kater, A. P. & Spaargaren, M., 1 Sep 2022, In: Leukemia. 36, 9, p. 2165-2176 12 p.

 

Treatment of relapsed and refractory Waldenstrom Macroglobulinemia. Amaador, K., Kersten, M. J., Minnema, M. C. & Vos, J. M. I., 2022, (E-pub ahead of print) In: Leukemia and Lymphoma.

 

Waldenström macroglobulinemia presenting as nephrotic syndrome: Renal heavy and light chain amyloidosis. Kwakernaak, A. J., Bernelot Moens, S. J., Hilhorst, M. L., Florquin, S., van de Donk, N. W. C. J. & Vos, J. M. I., May 2022, In: EJHaem. 3, 2, p. 565-566 2 p.

 

2021

A Major Subset of Mutated CLL Expresses Affinity-selected and Functionally Proficient Rheumatoid Factors. Janssen, J., Donner, N., Li, Z., Wormhoudt, T. A. M., Wagner, K., Guikema, J. E. J., van der Schoot, C. E., Kater, A. P., Feizi, T., Bende, R. J. & van Noesel, C. J. M., 2021, (E-pub ahead of print) In: HemaSphere. e550.

 

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Kater, A. P., Slinger, E., Cretenet, G., Martens, A. W., Balasubramanian, S., Leverson, J. D. & Eldering, E., 14 Dec 2021, In: BLOOD ADVANCES. 5, 23, p. 5410-5414 5 p.

 

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. Kersten, M. J., Driessen, J., Zijlstra, J. M., Plattel, W. J., Morschhauser, F., Lugtenburg, P. J., Brice, P., Hutchings, M., Gastinne, T., Liu, R., Burggraaff, C. N., Nijland, M., Tonino, S. H., Arens, A. I. J., Valkema, R., van Tinteren, H., Lopez-Yurda, M., Diepstra, A., De Jong, D. & Hagenbeek, A., 1 Apr 2021, In: Haematologica. 106, 4, p. 1129-1137 9 p.

 

Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. Schuster, S. J., Zhang, J., Yang, H., Agarwal, A., Tang, W., Martinez-Prieto, M., Bollu, V., Kuzan, D., Maziarz, R. T. & Kersten, M. J., 2021, (E-pub ahead of print) In: Leukemia & lymphoma.

 

Conditional relative survival in Waldenström’s macroglobulinaemia: a population-based study in The Netherlands. Amaador, K., Kersten, M. J., Visser, O., Posthuma, E. F. M., Minnema, M. C., Vos, J. M. I. & Dinmohamed, A. G., 2021, (E-pub ahead of print) In: British Journal of Haematology.

 

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma (Journal of Hematology & Oncology, (2021), 14, 1, (11), 10.1186/s13045-021-01031-3). Ren, Z., Lantermans, H., Kuil, A., Kraan, W., Arenzana-Seisdedos, F., Kersten, M. J., Spaargaren, M. & Pals, S. T., 1 Dec 2021, In: JOURNAL OF HEMATOLOGY & ONCOLOGY. 14, 1, 29.

 

Correction: Van bruggen et al. Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma (Cancers (2020), 12, (3837), 10.3390/cancers12123837). van Bruggen, J. A. C., Martens, A. W. J., Tonino, S. H. & Kater, A. P., 1 Oct 2021, In: Cancers. 13, 19, 4738.

 

Co-stimulatory versus cell death aspects of agonistic cd40 monoclonal antibody selicrelumab in chronic lymphocytic leukemia. Delgado, R., Kielbassa, K., ter Burg, J., Klein, C., Trumpfheller, C., de Heer, K., Kater, A. P. & Eldering, E., 2 Jun 2021, In: Cancers. 13, 12, 3084.

 

Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. Amaador, K., Vos, J. M. I., Pals, S. T., Kraan, W., Dobber, J. A., Minnema, M. C., Koene, H. R., de Bruin, P. C., Zwinderman, A. H. & Kersten, M. J., 2021, (E-pub ahead of print) In: Leukemia & lymphoma.

 

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Jalink, M., Berentsen, S., Castillo, J. J., Treon, S. P., Cruijsen, M., Fattizzo, B., Cassin, R., Fotiou, D., Kastritis, E., de Haas, M., Oosten, L. E. M., Frederiksen, H., Patriarca, A., D'Sa, S. & Vos, J. M. I., 18 Nov 2021, In: Blood. 138, 20, p. 2002-2005 4 p.

 

Halting targeted and collateral damage to red blood cells by the complement system. Jalink, M., de Boer, E. C. W., Evers, D., Havinga, M. Q., Vos, J. M. I., Zeerleder, S., de Haas, M. & Jongerius, I., 1 Dec 2021, In: Seminars in Immunopathology. 43, 6, p. 799-816 18 p.

 

Hematopoietic versus solid cancers and T cell dysfunction: Looking for similarities and distinctions. Montironi, C., Muñoz-Pinedo, C. & Eldering, E., 2 Jan 2021, In: Cancers. 13, 2, p. 1-20 20 p., 284.

 

Higher-order of chronic lymphocytic leukaemia (CLL) classification: shared antigenic specificities of stereotyped B-cell receptor subsets as defined by the European Research Initiative on CLL consortium. Bende, R. J., Janssen, J. & van Noesel, C. J. M., 2021, (E-pub ahead of print) In: British Journal of Haematology.

 

How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents. Driessen, J., Tonino, S. H., Moskowitz, A. J. & Kersten, M. J., 10 Dec 2021, In: Hematology (United States). 2021, 1, p. 240-246 7 p.

 

Human CXCR5+PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies. Hofland, T., Martens, A. W. J., van Bruggen, J. A. C., de Boer, R., Schetters, S., Remmerswaal, E. B. M., Bemelman, F. J., Levin, M-D., Bins, A. D., Eldering, E., Kater, A. P. & Tonino, S. H., Mar 2021, In: European Journal of Immunology. 51, 3, p. 703-713 11 p.

 

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma. Lantermans, H. C., Minderman, M., Kuil, A., Kersten, M-J., Pals, S. T. & Spaargaren, M., Mar 2021, In: Leukemia. 35, 3, p. 881-886 6 p.

 

Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations. Minderman, M., Amir, A., Kraan, W., Schilder-Tol, E. J. M., Oud, M. E. C. M., Scheepstra, C. G., Noorduyn, A. L., Kluin, P. M., Kersten, M. J., Spaargaren, M. & Pals, S. T., 30 Sep 2021, In: Blood. 138, 13, p. 1194-1197 4 p.

 

Kinase inhibitors developed for treatment of hematologic malignancies: Implications for immune modulation in COVID-19. Jacobs, C. F., Eldering, E. & Kater, A. P., 9 Feb 2021, In: BLOOD ADVANCES. 5, 3, p. 913-924 12 p.

 

Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989–2018 Amaador, K., Kersten, M. J., Visser, O., Brink, M., Posthuma, E. F. M., Minnema, M. C., Vos, J. M. I. & Dinmohamed, A. G., 2021, (E-pub ahead of print) In: British Journal of Haematology.

 

Prof. Anton Hagenbeek 1948-2021: Father of MRD and Lymphoma Expert. Löwenberg, B., Kersten, M. J., Gale, R. P. & van Oers, M., 1 Sep 2021, In: Leukemia. 35, 9, p. 2725-2726 2 p.

 

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL. Haselager, M., Thijssen, R., West, C., Young, L., van Kampen, R., Willmore, E., Mackay, S., Kater, A. & Eldering, E., May 2021, In: Cell death and differentiation. 28, 5, p. 1658-1668 11 p.

 

Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis. Ren, Z., Spaargaren, M. & Pals, S. T., 1 Apr 2021, In: Blood. 137, 13, p. 1713-1718 6 p.

 

The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. Ren, Z., Lantermans, H., Kuil, A., Kraan, W., Arenzana-Seisdedos, F., Kersten, M. J., Spaargaren, M. & Pals, S. T., 1 Dec 2021, In: JOURNAL OF HEMATOLOGY & ONCOLOGY. 14, 1, 11.

 

The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Leeksma, A. C., Derks, I. A. M., Kasem, M. H., Kilic, E., de Klein, A., Jager, M. J., van de Loosdrecht, A. A., Jansen, J. H., Navrkalova, V., Faber, L. M., Zaborsky, N., Egle, A., Zenz, T., Pospisilova, S., Abdel-Wahab, O., Kater, A. P. & Eldering, E., 29 Jan 2021, In: Frontiers in Oncology. 10, 609409.

 

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. Niemann, C. U., Levin, M-D., Dubois, J., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., Dobber, J. A., Poulsen, C. B., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J., Mattsson, M., Bellido, M., Tran, H. T. T., Nasserinejad, K. & Kater, A. P., 25 Feb 2021, In: Blood. 137, 8, p. 1117-1120 4 p.

 

What the Silent Retina Tells You: Serous Retinal Detachment in Waldenström’s Macroglobulinemia. Amaador, K., Diederen, R., Coumou, J. & Vos, J., Feb 2021, In: HemaSphere. 5, 2, p. e527

 

2020

Kersten Marie José, Spanjaart Anne Mea, Thieblemont Catherine CD19-directed CAR T-cell therapy in B-cell NHL Current opinion in oncology 2020;32 (5):408-417 [Pubmed]

 

Stevens Wendy B. C., Bakunina Katerina, Cuijpers Marloes, Chamuleau Martine, Beeker Aart, Fijnheer Rob, Hebart Holger, Visser Hein P. J., Doorduijn Jeanette K., Linton Kim, Dreyling Martin, de Jong Daphne, Kersten Marie José HOVON110/ReBeL Study: Results of the phase i part of a randomized phase I/II study of lenalidomide, rituximab with or without bendamustine in patients with relapsed/refractory follicular lymphoma HemaSphere 2020;4 (1) [Pubmed]

 

Lantermans Hildo C., Minderman Marthe, Kuil Annemieke, Kersten Marie-José, Pals Steven T., Spaargaren Marcel Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma Leukemia 2020 [Pubmed]

 

Bende Richard J., Janssen Jerry, Beentjes Anna, Wormhoudt Thera A. M., Wagner Koen, Haacke Erlin A., Kroese Frans G. M., Guikema Jeroen E. J., van Noesel Carel J. M. Salivary Gland Mucosa-Associated Lymphoid Tissue–Type Lymphoma From Sjögren’s Syndrome Patients in the Majority Express Rheumatoid Factors Affinity-Selected for IgG Arthritis & rheumatology (Hoboken, N.J.) 2020;72 (8):1330-1340 [Pubmed]

 

Joosten Sander P. J., Spaargaren Marcel, Clevers Hans, Pals Steven T. Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 2020;1874 (2) [Pubmed]

 

Vermaat Joost S., Somers Sebastiaan F., de Wreede Liesbeth C., Kraan Willem, de Groen Ruben A. L., Schrader Anne M. R., Kerver Emile D., Scheepstra Cornelis G., Berenschot Henriëtte, Deenik Wendy, Wegman Jurgen, Broers Rianne, de Boer Jan-Paul D., Nijland Marcel, van Wezel Tom, Veelken Hendrik, Spaargaren Marcel, Cleven Arjen H., Kersten Marie José, Pals Steven T. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis Haematologica 2020;105 (2):424-434 [Pubmed]

 

Minderman Marthe, Pals Steven T. Towards genomic-based prognostication and precision therapy for diffuse large B-cell lymphoma Haematologica 2020;105 (9):2194-2196 [Pubmed]

 

Martens Anne W. J., Janssen Susanne R., Derks Ingrid A. M., Adams Iii Homer C., Izhak Liat, van Kampen Roel, Tonino Sanne H., Eldering Eric, van der Windt Gerritje J. W., Kater Arnon P. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells Journal for immunotherapy of cancer 2020;8 (1) [Pubmed]

 

Hofland Tom, Martens Anne W. J., van Bruggen Jaco A. C., de Boer Renate, Schetters Sjoerd, Remmerswaal Ester B. M., Bemelman Frederike J., Levin Mark-David, Bins Adriaan D., Eldering Eric, Kater Arnon P., Tonino Sanne H. Human CXCR5+PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies European journal of immunology 2020 [Pubmed]

 

Haselager Marco V., Kater Arnon P., Eldering Eric Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? Frontiers in oncology 2020;10 [Pubmed]

 

Kater Arnon P., Wu Jenny Qun, Kipps Thomas, Eichhorst Barbara, Hillmen Peter, D'Rozario James, Assouline Sarit, Owen Carolyn, Robak Tadeusz, de la Serna Javier, Jaeger Ulrich, Cartron Guillaume, Montillo Marco, Dubois Julie, Eldering Eric, Mellink Clemens, van der Kevie-Kersemaekers Anne-Marie, Kim Su Young, Chyla Brenda, Punnoose Elizabeth, Bolen Christopher R., Assaf Zoe June, Jiang Yanwen, Wang Jue, Lefebure Marcus, Boyer Michelle, Humphrey Kathryn, Seymour John F. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study Journal of clinical oncology 2020;38 (34):4042-4054 [Pubmed]

 

Ossenkoppele G. J., Breems D. A., Stuessi G., van Norden Y., Bargetzi M., Biemond B. J., A von dem Borne P., Chalandon Y., Cloos J., Deeren D., Fehr M., Gjertsen B., Graux C., Huls G., Janssen J. J. J. W., Jaspers A., Jongen-Lavrencic M., de Jongh E., Klein S. K., van der Klift M., van Marwijk Kooy M., Maertens J., Michaux L., van der Poel M. W. M., van Rhenen A., Tick L., Valk P., Vekemans M. C., van der Velden W. J. F. M., de Weerdt O., Pabst T., Manz M., Löwenberg B., Breems D. A., Vekemans M. C., Moors I., van Obberg F., Maertens J. A., Hodossy B., Vansteenweghen S., Lammertijn L., Deeren D., Graux C., Sonet A., Triffet A., Gjertsen B. T., Bargetzi M., Passweg J., Biemond B. J. Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0) Leukemia 2020;34 (10) [Pubmed]

 

 

van Baarle Frank E. H. P., van de Weerdt Emma K., Suurmond Bram, Müller Marcella C. A., Vlaar Alexander P. J., Biemond Bart J. Bleeding assessment and bleeding severity in thrombocytopenic patients undergoing invasive procedures Transfusion 2020;60 (3):637-649 [Pubmed]

 

Tang Man Wai, Nur Erfan, Biemond Bart J. Immune Thrombocytopenia during Pregnancy due to COVID-19 American journal of hematology 2020 [Pubmed]

 

Omar Saïd Z., Blom Bianca, Hazenberg Mette D. Innate lymphoid cells in treatment-induced gastrointestinal pathogenesis Current opinion in supportive and palliative care 2020;14 (2):135-141 [Pubmed]

 

van Lier Yannouck F., de Bree Godelieve J., Jonkers René E., Roelofs Joris J. T. H., ten Berge Ineke J. M., Rutten Caroline E., Nur Erfan, Kuijpers Taco W., Hazenberg Mette D., Zeerleder Sacha S. Allogeneic hematopoietic cell transplantation in the management of GATA2 deficiency and pulmonary alveolar proteinosis Clinical immunology (Orlando, Fla.) 2020;218 [Pubmed]

 

Stratigopoulou Maria, van Dam Tijmen P., Guikema Jeroen E. J. Base Excision Repair in the Immune System: Small DNA Lesions With Big Consequences Frontiers in immunology 2020;11 [Pubmed]

 

Voermans Carlijn, Hazenberg Mette D. Cellular therapies for graft-versus-host disease: a tale of tissue repair and tolerance Blood 2020;136 (4):410-417 [Pubmed]

 

van Lier Yannouck F., Davids Mark, Haverkate Nienke J. E., de Groot Pieter F., Donker Marjolein L., Meijer Ellen, Heubel-Moenen Floor C. J. I., Nur Erfan, Zeerleder Sacha S., Nieuwdorp Max, Blom Bianca, Hazenberg Mette D. Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients Science translational medicine 2020;12 (556) [Pubmed]

 

Leeksma Alexander C., Baliakas Panagiotis, Moysiadis Theodoros, Puiggros Anna, Plevova Karla, van der Kevie-Kersemaekers Anne-Marie, Posthuma Hidde, Rodriguez-Vicente Ana E., Tran Anh Nhi, Barbany Gisela, Mansouri Larry, Gunnarsson Rebeqa, Parker Helen, van den Berg Eva, Bellido Mar, Davis Zadie, Wall Meaghan, Scarpelli Ilaria, Österborg Anders, Hansson Lotta, Jarosova Marie, Ghia Paolo, Poddighe Pino, Espinet Blanca, Pospisilova Sarka, Tam Constantine, Ysebaert Loïc, Nguyen-Khac Florence, Oscier David, Haferlach Claudia, Schoumans Jacqueline, Stevens-Kroef Marian, Eldering Eric, Stamatopoulos Kostas, Rosenquist Richard, Strefford Jonathan C., Mellink Clemens, Kater Arnon P. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: A multi-center study Haematologica 2020;105 (5) [Pubmed]

 

2019

 

Hoving V. , Kersten M. J. , Minnema M. C., de Bruin P. C., Vos Josephine Hoe behandel ik IgM-M-proteïne-gerelateerde AL-amyloïdose? Nederlands tijdschrift voor hematologie 2019;16:87-91

 

Hagenbeek Anton, Mooij Hans, Zijlstra Josée, Lugtenburg Pieternella, van Imhoff Gustaaf, Nijland Marcel, Tonino Sanne, Hutchings Martin, Spiering Marjolein, Liu Roberto, van Tinteren Harm, Kersten Marie José Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study Haematologica 2019;104 (4):e151-e153 [Pubmed]

 

Kleijwegt Fleur S, Roda Afnan Abdul, Rolvink José, Kater Arnon P, Kersten Marie José, Vos Josephine M I Rare but Serious: Ibrutinib Induced Liver Failure HemaSphere 2019;3 (6):e307 [Pubmed]

 

Kersten Marie José, van Ettekoven Cornelis N., Heijink D. Ianne M. Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity BMJ case reports 2019;12 (11) [Pubmed]

 

de Jong Greta, Janssen Jeroen J. W. M., Biemond Bart J., Zeerleder Sacha S., Ossenkoppele Gert J., Visser Otto, Nur Erfan, Meijer Ellen, Hazenberg Mette D. Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies European journal of haematology 2019;103 (5):491-499 [Pubmed]

 

Hazenberg Mette D., Haverkate Nienke J. E., van Lier Yannouck F., Spits Hergen, Krabbendam Lisette, Bemelman Willem A., Buskens Christianne J., Blom Bianca, Shikhagaie Medya M. Human ectoenzyme-expressing ILC3: Immunosuppressive innate cells that are depleted in graft-versus-host disease Blood advances 2019;3 (22):3650-3660 [Pubmed]

 

Hofland Tom, de Weerdt Iris, ter Burg Hanneke, de Boer Renate, Tannheimer Stacey, Tonino Sanne H., Kater Arnon P., Eldering Eric Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes Journal of immunology (Baltimore, Md. 2019;203 (8):2100-2109 [Pubmed]

 

van Oers Marinus, Smolej Lukas, Petrini Mario, Offner Fritz, Grosicki Sebastian, Levin Mark-David, Davis Jaclyn, Banerjee Hiya, Stefanelli Tommaso, Hoever Petra, Geisler Christian Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study Blood cancer journal 2019;9 (12) [Pubmed]

 

de Weerdt Iris, Hofland Tom, de Boer Renate, Dobber Johan A., Dubois Julie, van Nieuwenhuize Denise, Mobasher Mehrdad, de Boer Fransien, Hoogendoorn Mels, Velders Gerjo A., van der Klift Marjolein, Remmerswaal Ester B. M., Bemelman Frederike J., Niemann Carsten U., Kersting Sabina, Levin Mark-David, Eldering Eric, Tonino Sanne H., Kater Arnon P. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment Blood advances 2019;3 (17):2642-2652 [Pubmed]

 

Hofland Tom, Eldering Eric, Kater Arnon P., Tonino Sanne H. Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia International journal of molecular sciences 2019;20 (17) [Pubmed]

 

Hofland Tom, Endstra Sanne, Gomes Calum K P, de Boer Renate, de Weerdt Iris, Bobkov Vladimir, Riedl Jurgen A, Heukers Raimond, Smit Martine J, Eldering Eric, Levin Mark-David, Kater Arnon P, Tonino Sanne H Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling HemaSphere 2019;3 (6):e308 [Pubmed]

 

Joosten Sander P. J., Mizutani Tomohiro, Spaargaren Marcel, Clevers Hans, Pals Steven T. MET Signaling Overcomes Epidermal Growth Factor Receptor Inhibition in Normal and Colorectal Cancer Stem Cells Causing Drug Resistance Gastroenterology 2019;157 (4):1153-1155.e1 [Pubmed]

 

Slot L. M., Wormhoudt T. A. M., Kwakkenbos M. J., Wagner K., Ballering A., Jongejan A., van Kampen A. C. M., Guikema J. E. J., Bende R. J., van Noesel C. J. M. De novo gene mutations in normal human memory B cells Leukemia 2019;33 (5):1219-1230 [Pubmed]

 

van Andel H, Kocemba KA, Spaargaren M, Pals ST. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options. Leukemia. 2019 May;33(5):1063-1075. doi: 10.1038/s41375-019-0404-1. Epub 2019 Feb 15. Review.[Pubmed]

 

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. Blood. 2019 May 10. pii: blood.2018885863. doi: 10.1182/blood.2018885863. [Pubmed]

 

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2. [Pubmed]

 

Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, Verdugo M, Wu J, Punnoose EA, Jiang Y, Wang J, Boyer M, Humphrey K, Mobasher M, Kipps TJ. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol. 2019 Feb 1;37(4):269-277. doi: 10.1200/JCO.18.01580. [Pubmed].

 

Kater AP, Brown JR. Ibrutinib: searching for a partner drug. Lancet Oncol. 2019 Jan;20(1):3-5. doi: 10.1016/S1470-2045(18)30861-1. [Pubmed].

 

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. [Pubmed].

 

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. [Pubmed]

 

Blom B, Van Hoeven V, Hazenberg MD. ILC in hematologic malignancies: tumor cell killers and tissue healers. Seminars in Immunology, accepted for publication, 2019.

 

Bartels L, De Jong G, Gillissen MA, Yasuda E, Kattler V, Bru C, Moiset G, Bakker AQ, Van Helden PM, Villaudy J, Hazenberg MD, Spits H, Wagner K. Retargeting T-cells to a sialylated epitope on CD43 present in acute myeloid leukemia using a chemo-enzymatically linked bispecific antibody. Cancer Research, epub ahead of print 2019.

 

Wardill HR, Secombe KS, Bryant R, Hazenberg MD, Costello SP. Adjunctive fecal microbiota transplantation in supportive oncology: emerging indications and considerations in immunocompromised patients. EBioMed, epub ahead of print 2019. [Pubmed]

 

Langedijk AC, Van Aalst M, Meek B, Van Leeuwen EMM, Zeerleder SS, Hazenberg MD, Grobusch MP, Goorhuis A. Pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation. Vaccine 2019; 37:510-515.

 

2018

Anton Hagenbeek, Hans Mooij, Josée Zijlstra, Pieternella Lugtenburg, Gustaaf Van Imhoff, Marcel Nijland, Sanne Tonino, Martin Hutchings, Marjolein Spiering, Roberto Liu, Harm Van Tinteren, Marie-José Kersten, Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study ASH Annual Meeting Abstract 2018 [link]

 

Anton Hagenbeek, Josée M Zijlstra, Wouter J Plattel, Franck Morschhauser, Petronella J Lugtenburg, Pauline Brice, Martin Hutchings, Thomas Gastinne, Roberto D Liu, Coreline N Burggraaf, Marcel Nijland, Sanne H Tonino, Harm van Tinteren, Marta I Lopez Yurda and Marie José Kersten, Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study [link]

 

de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland P, de Bruin RCG, Remmerswaal EBM, ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP, Improving CLL Vγ9Vδ2-T cell fitness for cellular therapy by ex vivo activation and ibrutinib, Blood 2018 :blood-2017-12-822569; doi: https://doi.org/10.1182/blood-2017-12-822569 [PubMed]

 

Ren Z, van Andel H, de Lau W, Hartholt RB, Maurice MM, Clevers H, Kersten MJ, Spaargaren M, Pals ST, Syndecan-1 promotes Wnt/beta-catenin signaling in multiple myeloma by presenting Wnts and R-spondins. BLOOD 2018;131 (9):982-994 [PubMed]

 

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP, Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. LEUKEMIA 2018;ahead of print [PubMed]

 

Nijland ML, Koens L , Pals ST, ten Berge IJM, Bemelman FJ, Kersten MJ, Clinicopathological characteristics of T-cell non-Hodgkin lymphoma arising in patients with immunodeficiencies: a single-center case series of 25 patients and a review of the literature. HAEMATOLOGICA 2018;103 (3):486-496 [PubMed]

 

Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ, Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. LANCET HAEMATOL 2018;5 (4):e170-e180 [PubMed]

 

de Back TR, Kater AP, Tonino SH, Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations. EXPERT REV HEMATOL 2018;11 (8):613-624 [PubMed]

 

Vlijm-Kievit A, Jorna NGE, Moll E, Pajkrt E, Pals ST, Middeldorp S, Biemond BJ, Zeerleder SS, Tio MA, Kemper EM, Hazenberg MD, Acute lymphoblastic leukemia during the third trimester of pregnancy. LEUKEMIA LYMPHOMA 2018;59 (5):1274-1276 [PubMed]

 

Vos JM, Notermans NC, D'Sa S, Lunn MP, van der Pol WL, Kraan W, Reilly MM, Chalker J, Gupta R, Kersten MJ, Pals ST, Minnema MC, High prevalence of the MYD88 L265P mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. J NEUROL NEUROSUR PS 2018;89 (9):1007-+ [PubMed]

 

Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, Gao J, Dreiling L, Xin Y, Doorduijn JK, Kersten MJ, Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. BLOOD CANCER J 2018;8 (2):16 [PubMed]

 

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, van Gelder M, Hoogendoorn M, de Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting SA, Levin MD, Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. HAEMATOLOGICA 2018;ahead of print [PubMed]

 

Slot LM, Wormhoudt TAM, Kwakkenbos MJ, Wagner K, Ballering A, Jongejan A, van Kampen ACM, Guikema JEJ, Bende RJ, van Noesel CJM, De novo gene mutations in normal human memory B cells. LEUKEMIA 2018;ahead of print [PubMed]

 

Kersting S, Neppelenbroek SIM, Visser HPJ, van Gelder M, Levin MD, Mous R, Posthuma W, van der Straaten HM, Kater AP, Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. CL LYMPH MYELOM LEUK 2018;18 (1):52-57 [PubMed]

 

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP, Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. NEW ENGL J MED 2018;378 (12):1107-1120 [PubMed]

 

Seymour JF, Mobasher M, Kater AP, Venetoclax-Rituximab in Chronic Lymphocytic Leukemia REPLY. NEW ENGL J MED 2018;378 (22):2143-+ [PubMed]

 

Gillissen MA, Kedde M, Jong Gd, Moiset G, Yasuda E, Levie SE, Bakker AQ, Claassen YB, Wagner K, Böhne M, Hensbergen PJ, Speijer D, van Helden PM, Beaumont T, Spits H, Hazenberg MD, AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses. BLOOD 2018;131 (1):131-143 [PubMed]

 

van Hoeven V, Munneke JM, Cornelissen AS, Omar SZ, Spruit MJ, Kleijer M, Bernink JH, Blom B, Voermans C, Hazenberg MD, Mesenchymal Stromal Cells Stimulate the Proliferation and IL-22 Production of Group 3 Innate Lymphoid Cells. J IMMUNOL 2018;201 (4):1165-1173 [PubMed]

 

Vlijm-Kievit A, Jorna NGE, Moll E, Pajkrt E, Pals ST, Middeldorp S, Biemond BJ, Zeerleder SS, Tio MA, Kemper EM, Hazenberg MD, Acute lymphoblastic leukemia during the third trimester of pregnancy. LEUKEMIA LYMPHOMA 2018;59 (5):1274-1276 [PubMed]

Meer publicaties

  • Binnenkort een volledige lijst publicaties vanuit de afdeling Hematologie en de Experimentele Immunologie
  • Binnenkort een volledige lijst publicaties vanuit de afdeling Pathologie